Theralink Technologies, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021
February 19, 2022 at 02:31 am IST
Share
Theralink Technologies, Inc. reported earnings results for the first quarter ended December 31, 2021. For the first quarter, the company reported sales was USD 0.078975 million compared to USD 0.00979 million a year ago. Net loss was USD 1.51 million compared to USD 1.42 million a year ago.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.